Spelman, T. Et Al. 2016. Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. NEUROLOGY-CLINICAL PRACTICE , vol.6, no.2 , 102-115.

Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Belachew, S.(2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. NEUROLOGY-CLINICAL PRACTICE , vol.6, no.2, 102-115.

Spelman, Tim Et Al. "Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS," NEUROLOGY-CLINICAL PRACTICE , vol.6, no.2, 102-115, 2016

Spelman, Tim Et Al. "Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS." NEUROLOGY-CLINICAL PRACTICE , vol.6, no.2, pp.102-115, 2016

Spelman, T. Et Al. (2016) . "Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS." NEUROLOGY-CLINICAL PRACTICE , vol.6, no.2, pp.102-115.

@article{article, author={Tim Spelman Et Al. }, title={Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS}, journal={NEUROLOGY-CLINICAL PRACTICE}, year=2016, pages={102-115} }